Clinical trial · no report yet · Phase 3
CheckMate 577
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
- NCT02743494 ↗
- Completed
- Bristol-Myers Squibb
- 194 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 67 | |
| Podcasts | 67 | |
| X threads | 60 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Advanced Cancer
- Interventions
- Nivolumab; Placebo
- Arms
- Nivolumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 794
- Primary outcomes
- Disease-free Survival (DFS)
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Jul 14, 2016
- Primary completion
- May 12, 2020
- Results posted
- Yes
- Registry record
- NCT02743494 · updated Nov 18, 2025
Publications
linked from the registry- Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. PubMed 33789008